HIF1A and neoplasm: Emerging strategies to overcome hypoxia-mediated resistance focus on tumor vasculature normalization using anti-angiogenic agents (e.g., axitinib), HIF-1α signaling inhibition via digoxin analogs, and lactate export modulation through monocarboxylate transporter (MCT) blockade.